Scholarlink

<p>Ischemic stroke remains a leading cause of mortality and long-term disability worldwide, necessitating innovative therapeutic approaches beyond conventional treatments. RNA-based therapeutics have emerged as a promising strategy to modulate key pathological processes involved in stroke, including neuroinflammation, apoptosis, oxidative stress, and neurovascular dysfunction. Small interfering RNA (siRNA) and microRNA (miRNA)-based therapies enable post-transcriptional gene silencing to downregulate deleterious pathways, while messenger RNA (mRNA) and long non-coding RNA (lncRNA)-based strategies promote neuroprotection and neuronal recovery. Despite significant preclinical advancements, several challenges hinder clinical translation, including blood-brain barrier (BBB) permeability, RNA stability, immune responses, off-target effects, and efficient intracellular delivery. Recent breakthroughs in nanoparticle-based delivery systems, exosome-mediated transport, and CRISPR-based RNA editing offer novel solutions to these limitations, paving the way for precision medicine approaches in stroke treatment. Future research must focus on optimizing RNA formulations, refining delivery mechanisms, and conducting rigorous clinical trials to establish their safety and efficacy in stroke patients. If successfully translated into clinical practice, RNA-based therapeutics have the potential to revolutionize stroke management by providing targeted, disease-modifying interventions that enhance functional recovery and reduce long-term neurological deficits.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

RNA-based approaches for neuroprotection and recovery in ischemic stroke: current evidence and future directions

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月19日

查看全文
  • Nicholas Aderinto,
  • Emmanuel Adeoba Babawale,
  • Gbolahan Olatunji,
  • Emmanuel Kokori,
  • Festus Oluseye Babarinde,
  • Wendy Donaldy,
  • Ololade Wiquoyat Oyesiji,
  • Fransiwa Valerie Vande-Pallen,
  • Franklin Andibanbang,
  • Alexander Audu Obaje,
  • Oluwatobi Adeola Olaomi,
  • Alexander Idu Entonu,
  • Badrudeen Olalekan Alabi,
  • Ayoola Ikeoluwa,
  • Okikiola Sobuur Fagbolade,
  • Kingdom Perelade Jojo,
  • Israel Charles Abraham,
  • Chidinma Udojike

摘要

Ischemic stroke remains a leading cause of mortality and long-term disability worldwide, necessitating innovative therapeutic approaches beyond conventional treatments. RNA-based therapeutics have emerged as a promising strategy to modulate key pathological processes involved in stroke, including neuroinflammation, apoptosis, oxidative stress, and neurovascular dysfunction. Small interfering RNA (siRNA) and microRNA (miRNA)-based therapies enable post-transcriptional gene silencing to downregulate deleterious pathways, while messenger RNA (mRNA) and long non-coding RNA (lncRNA)-based strategies promote neuroprotection and neuronal recovery. Despite significant preclinical advancements, several challenges hinder clinical translation, including blood-brain barrier (BBB) permeability, RNA stability, immune responses, off-target effects, and efficient intracellular delivery. Recent breakthroughs in nanoparticle-based delivery systems, exosome-mediated transport, and CRISPR-based RNA editing offer novel solutions to these limitations, paving the way for precision medicine approaches in stroke treatment. Future research must focus on optimizing RNA formulations, refining delivery mechanisms, and conducting rigorous clinical trials to establish their safety and efficacy in stroke patients. If successfully translated into clinical practice, RNA-based therapeutics have the potential to revolutionize stroke management by providing targeted, disease-modifying interventions that enhance functional recovery and reduce long-term neurological deficits.